Polyethylenimine–carbon nanotube nanohybrids for siRNA-mediated gene silencing at cellular level
- 7 February 2011
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 3 (4) , 1461-1464
Abstract
Carbon nanotubes (CNTs) covalently modified with low molecular weight polyethylenimine (PEI) are able to bind and deliver siRNA to cells with higher efficacy than a reference lipidic carrier. The performances of the nanohybrid are rationalized by the combination of the cell penetration and endosomal escape properties of CNTs and PEI, respectively.Keywords
This publication has 36 references indexed in Scilit:
- Proton Sponge Trick for pH-Sensitive Disassembly of Polyethylenimine-Based siRNA Delivery SystemsBioconjugate Chemistry, 2010
- Formulation and Delivery of Splice-Correction Antisense Oligonucleotides by Amino Acid Modified PolyethylenimineMolecular Pharmaceutics, 2010
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Nanotubes Functionalized with Lipids and Natural Amino Acid Dendrimers: A New Strategy to Create Nanomaterials for Delivering Systemic RNAiBioconjugate Chemistry, 2009
- Cancer therapy: Small 10/2009Small, 2009
- Knockdown of TRPC3 with siRNA coupled to carbon nanotubes results in decreased insulin‐mediated glucose uptake in adult skeletal muscle cellsThe FASEB Journal, 2009
- Self‐Assembling Polyethylenimine Derivatives Mediate Efficient siRNA Delivery in Mammalian CellsChemBioChem, 2008
- Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genesBiochemical and Biophysical Research Communications, 2008
- Enhanced Cell Penetration of Acid-Degradable Particles Functionalized with Cell-Penetrating PeptidesBioconjugate Chemistry, 2008
- Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNAMolecular Cancer Therapeutics, 2007